BusinessBioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone ImplantBy Nasdaq OMXApr 30, 2018, 11:01 AM UTC
BusinessBioCorRx to Exhibit at ASAM 49th Annual Conference in San Diego, CaliforniaBy Nasdaq OMXApr 10, 2018, 11:30 AM UTC
BusinessBioCorRx Extends Service Agreement with Dr. Balbir S. Brar as VP of Drug Development Following Pre-IND Meeting with the U.S. FDABy Nasdaq OMXFeb 8, 2018, 12:31 PM UTC
BusinessBioCorRx Completes Pre-IND Meeting with FDA; Reports Company to Move Forward with BICX102By Nasdaq OMXJan 26, 2018, 12:30 PM UTC
BusinessBioCorRx CEO, Brady Granier, Appears on Fox & Friends to Discuss the Opioid EpidemicBy Nasdaq OMXJan 2, 2018, 12:30 PM UTC
BusinessBioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102By Nasdaq OMXDec 19, 2017, 12:30 PM UTC
